KMCRIC

Omega-3 for the prevention of cardiovascular diseases: meta-analysis and trial-sequential analysis.

Cabiddu MF, Russi A, Appolloni L, Mengato D, Chiumente M.

Eur J Hosp Pharm.

2022

29(3)

134-8.

10.1136/ejhpharm-2020-002207.

32546568

http://www.ncbi.nlm.nih.gov/pubmed/32546568

Cardiovascular Diseases* / diagnosis
Cardiovascular Diseases* / drug therapy
Cardiovascular Diseases* / prevention & control
Fatty Acids, Omega-3* / therapeutic use
Humans
Primary Prevention / methods
Randomized Controlled Trials as Topic
Secondary Prevention / methods

cardiac epidemiology; coronary heart disease; dietetics; evidence-based medicine; nutrition; research methods; statistics

없음

N

Objectives: The effectiveness of omega-3 fatty acids (PUFAs) in cardiovascular diseases (CVD) remains a matter of debate. The aim of this work was to evaluate PUFAs in the reduction of cardiovascular mortality in primary and secondary prevention of CVD to determine if further original studies are needed or the available data can be considered conclusive.

Methods: A meta-analysis was performed according to a dichotomous endpoint followed by a trial-sequential analysis (TSA). Clinical data were identified through a PubMed search based on the following keywords: omega-3 fatty acids; cardiovascular disease; death; and cardiovascular risk. The clinical trials identified by this procedure were subjected to standard meta-analysis and TSA.

Results and conclusions: A total of 11 randomised studies for 100 609 patients were analysed. Our meta-analysis showed a statistically significant reduction in mortality due to cardiovascular issues (RR=0.937; 95% CI: 0.88 to 0.98; P=0.018). The TSA indicated that no further trials are needed to better evaluate the efficacy of PUFAs in preventing death related to CVD.

© European Association of Hospital Pharmacists 2022. No commercial re-use. See rights and permissions. Published by BMJ.

N

영어